IJARP
SJIF(2020): 5.702

International Journal of Advanced Research and Publications

High Quality Publications & World Wide Indexing!

Evaluation Of Uric Acid Among Sudanese Patients With Chronic Kidney Disease

Volume 3 - Issue 12, December 2019 Edition
[Download Full Paper]

Author(s)
Mohammed Yasein Mohammed Babiker
Keywords

Abstract
Background: Chronic kidney disease (CKD) is an international public health problem affecting 5-10% of the world population. As kidney function declines Methods: This study is case-control study conducted in Ibn sina hospital, Military hospital and Ribat specialized hospital within six months from October 2016 to March 2017. The aim of this study is to evaluate the effect of uric acid in Sudanese patients with chronic kidney disease. A total of 100 patients (60 male, 40 female) and 50 healthy individuals as control group (30 male, 20 female). Results: in this study the level of uric acid was significantly increased in CKD patients compared to control group, with the P-value (0.000). Conclusion: based upon the finding of this study, hyperuricemia as most cause of cardiovascular disease in patients with chronic kidney disease.
References
[1] Addadi F., Alatab S., Pasha F., Ganji M.R., Soleimanian T. (2014). The Effect of Treatment with N acetylcysteine on the Serum Levels of C - reactive protein and Interleukin-6 in Patients on Hemodialysis. Saudi Journal of Kidney Diseases and Transplantation. 25(1): P.66-72.
[2] Adejumo A.O, Okaka I.E., Okwuonu G.C., Ikponmwosa O. Iyawe and Oluwole O.O., (2016). Serum C-reactive protein levels in pre-dialysis chronic kidney disease patients in southern Nigeria. 50(1). P.31-38.
[3] AL-Sharqi A. H. S., AL-Najar SH. W. E. and AL-Jaff H. K. S. (2015). Lipid profiles and kidney function in chronic renal failure Iraqi patient pre peritoneal dialysis or hemodialysis. International Journal of Advanced Research, Volume 3, Issue 11, P. 776 – 780.
[4] Alaraj. M., Al-Tamimi N., Abu Rayyan W., Alshammari F., Hossain A., Al Hadires T., Alanazi M., Al-Trad B., Alfouzan F., Abu Rayyan A., Al-Shammary A., Alanazi1 M., Ginawi I., Al Hazmi A. (2016). Role of Age and Uric Acid Levels on Dialysis Efficacy among End Stage Renal Disease Patients in Saudi Arabia. Journal of Research in Medical and Dental Science. Vol. 4. Issue 2. P. 92-96.
[5] Albertoni A. G., Borges T. F., and Schor N. (2012). Uric Acid and Renal Function, Diseases of Renal Parenchyma, Prof. Manisha Sahay (Ed.), InTech. P. 57-74.
[6] Bhatti K.N, Galougahi K.K, Paz Y, Nazif T, Moses W.J, Leon B.M, Stone W.G, Kirtane J.A, Karmpaliotis D, Bokhari S, Hardy A.M, Dube G, Mohan S, Ratner E.L, Cohen J.D, Ali A.Z and DPhil. (2016). Diagnosis and Management of Cardiovascular Disease in Advanced and End-Stage Renal Disease. P.1-14.
[7] Bishop M L, Fody E and Schoeff L E. (2010). Bishop’s clinical chemistry. 6th ed. China: Lippinocott Williams and Wilkins. P. 220-368, 570-587.
[8] Denise C. C., Dorin T., Raluca P., Mirela G., Emilian C. And Grigore D. (2016). Body Mass Index and the Relationship with Chronic Kidney Disease in a Tertiary Care Hospital in Romania. Acta Medica Marisiensis. 62(2): P. 225-229.
[9] Ding, D., Wang M., Su D., Hong C., Li X., Yang Y., Zhang Y., Hu G. and Ling W. (2015). Body Mass Index, High-Sensitivity C - reactive protein and Mortality in Chinese with Coronary Artery Disease.
[10] Dungey M, Hull L.K, Smith C.A, Burton O.J and Bishop C.N. (2013). Inflammatory Factors and Exercise in Chronic Kidney Disease. International Journal of Endocrinology. P.1-12.
[11] Elzain S., Balla H. and Ismail A. (2016). Impact of Hemodialysis on Serum Zinc and Copper Level in CKD Patients. Journal of Applied Pharmaceutical Science. 6. (04). p. 165-168.
[12] Goldberg I. and Krause I. (2016). The role of gender in chronic kidney disease. European Medical Journal.1. (2): P. 58-64.
[13] Herzog , Asinger W.R, Berger K.A, Charytan M.D, Dı´ez J, Hart G.R, Eckardt K, Kasiske L.B, McCullough A.P, Passman S.R, DeLoach S.S, Pun H.P and Ritz. E. (2011). Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes. International Society of Nephrology. P.1-15.
[14] Higgins And Chris. (2016). Urea and the clinical value of measuring blood. Acute care testing, p. 1-6.
[15] Hjelmesæth J., Røislien J., Nordstrand N., Hofsø D., Hager H. and Hartmann A. (2010). Low serum creatinine is associated with type 2diabetes in morbidly obese women and men: across-sectional study. BMC Endocrine Disorders. 10(6). P. 1-6.
[16] KDIGO. Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treaatment of chronic kidney disease-meniral and bone disorder (CKD-MBD). (2009). Official Journal Of The International Society of Nephrology. Vol.76. supplement 113, chapter 1. P.3.
[17] Kumar S. B, Shobharani.B. (2015). Comparative Study of Hscrp in Chronic Kidney Disease. IOSR Journal Of Pharmacy, July, Volume 5(7), P. 08-12.
[18] McFarlin K. B.,Flynn G. M., Campbell W. W., Craig A. B., Robinson P. J., Stewart K. L., Timmerman L. K., and Coen M. P. (2006). Physical Activity Status, But Not Age, Influences Inflammatory Biomarkers and Toll-Like Receptor 4. Journal of Gerontology. 2006, Vol. 61A, No. 4, P. 388–393.
[19] Mendelssohn C. D., Brownscombe M. L., Greenberg E. D. And Levin A. (1999). Elevated levels of serum creatinine:. Canadian Medical Association, 161 (4), p. 413-417.
[20] Noor U. A., Mahmood T. M., Asad J. M., Zafar M. And Raja M. A. (2014). Evaluating Urea and Creatinine Levels in Chronic Renal Failure Pre and Post Dialysis:. Journal Of Cardiovascular Disease, 2(2), p. 2330-4596.
[21] Parmar A. J., Sagar R. A., Kapadia S., Joshi A. and Chakrabarti M. (2014). Study of Parathyroid Hormone, Total Calcium, Creatinine and Urea in Chronic Kidney Disease. Int J Res Med. 3(2). P. 116-118.
[22] Rebić D. and Rašić S. (2014). Cardiovascular Remodelling In Chronic Kidney Disease. European Medical Journal. 1: P. 113-119.
[23] Roozbeh J., Sagheb M. M., Vafaie E. (2015). The association between blood pressure level and serum uric acid concentration in hemodialysis patients. Journal of Nephropathology. 4(3): P. 85-90.
[24] Sathi1 S, Sunder S, MahapatraH, Rajesh J, Sharma N, Verma H, Venkataramanan K, Gupta A, Prabhu K, Daksh S, Ram P and Wardhan H. (2014).Role of novel cardiac biomarkers in prediction of cardiovascular risk in pre-dialysis CKD patients by their correlations with left ventricular mass index. Clinical Nephrology and Urology Science. 1: (8). P.1-8.
[25] Shi B., Zhaohui Ni Z., Hong Cai H.,Minfang Zhang M., Wang S. Q. And Cao L. (2010). High-Sensitivity C-Reactive Protein: An Independent Risk Factor. Journal of Biomedicine and Biotechnology, Volume 2010, p. 1-5.
[26] Stenvinkel P, Carrero J.J, Axelsson J, Lindholm B, Heimbu¨ rger O, and Ziad Massy. (2008). Emerging Biomarkers for Evaluating Cardiovascular Risk in the Chronic Kidney Disease Patient. American Society of Nephrology. 3: P.505-521.
[27] Zahed N., Ghassami M. and Nikbakht H. (2016). Effects of coenzyme Q10 supplementation on C-reactive protein and homocysteine as the inflammatory markers in hemodialysis patients; a randomized clinical trial. Journal of Nephropathology. 5(1). P. 38-43.